Neurocrine (NB3) Stock Forecast & Price Target

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NB3 Analyst Ratings

Strong Buy

23 Buy

3 Hold

0 Sell

Based on 26 analysts giving stock ratings to

Neurocrine

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NB3 Stock 12 Month Forecast

Average Price Target

€183.81

▲(36.51% Upside)

Based on 26 Wall Street analysts offering 12 month price targets for Neurocrine in the last 3 months. The average price target is €183.81 with a high forecast of €222.12 and a low forecast of €144.86. The average price target represents a 36.51% change from the last price of €134.65.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"109":"€109","166":"€166","223":"€223","137.5":"€137.5","194.5":"€194.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":222.12213683,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€222.12</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":183.8082631096,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€183.81</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":144.86226315,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€144.86</span>\n  </div></div>","useHTML":true}}],"tickPositions":[109,137.5,166,194.5,223],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,131.55,138.51708744846155,145.4841748969231,152.45126234538463,159.41834979384615,166.3854372423077,173.35252469076923,180.31961213923077,187.2866995876923,194.25378703615382,201.22087448461536,208.1879619330769,215.15504938153845,{"y":222.12213683,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,131.55,135.56986639304617,139.58973278609233,143.60959917913846,147.6294655721846,151.64933196523077,155.66919835827693,159.6890647513231,163.70893114436925,167.7287975374154,171.74866393046153,175.7685303235077,179.78839671655385,{"y":183.8082631096,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,131.55,132.5740202423077,133.59804048461538,134.62206072692308,135.64608096923078,136.67010121153845,137.69412145384615,138.71814169615385,139.74216193846155,140.76618218076922,141.79020242307692,142.81422266538462,143.8382429076923,{"y":144.86226315,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":118.15,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.25,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.85,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.1,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":120.75,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.15,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.6,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.2,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.9,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137.6,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":146.05,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":144.9,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":131.55,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€222.12

Average Price Target€183.81

Lowest Price Target€144.86

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Jeffrey Walch

Bernstein

€191.39

Buy

42.14%

Upside

Reiterated

09/25/26

Bernstein Remains a Buy on Neurocrine (NBIX)

Brian Abrahams

RBC Capital

€173.83→€164.18

Buy

21.93%

Upside

Reiterated

09/21/26

Neurocrine (NBIX) Gets a Buy from RBC Capital

Unknown Analyst

CCB Intl.

Not Ranked

CCB Intl.

€165.06

Buy

22.58%

Upside

Initiated

09/18/26

Neurocrine (NBIX) Receives a Buy from CCB Intl.

Sean Laaman

Morgan Stanley

€159.79→€160.67

Hold

19.32%

Upside

Assigned

09/11/26

Neurocrine price target raised to $183 from $182 at Morgan StanleyNeurocrine price target raised to $183 from $182 at Morgan Stanley

Yigal Nochomovitz

Citi

€218.61→€222.12

Buy

64.96%

Upside

Reiterated

09/04/26

Neurocrine price target raised to $253 from $249 at CitiNeurocrine price target raised to $253 from $249 at Citi

Cory Kasimov

Evercore ISI

€184.37→€188.76

Buy

40.19%

Upside

Reiterated

08/17/26

Analysts Offer Insights on Healthcare Companies: OmniAb (NASDAQ: OABI), Neurocrine (NASDAQ: NBIX) and Evaxion Biotech (NASDAQ: EVAX)

Evan Seigerman

BMO Capital

€166.81

Hold

23.88%

Upside

Reiterated

08/17/26

Neurocrine (NBIX) Gets a Hold from BMO Capital

David Hoang

Deutsche Bank

€166.81→€144.86

Hold

7.58%

Upside

Assigned

08/13/26

Deutsche Bank Sticks to Its Hold Rating for Neurocrine (NBIX)

Anupam Rama

J.P. Morgan

€162.42→€190.52

Buy

41.49%

Upside

Reiterated

08/06/26

J.P. Morgan Reaffirms Their Buy Rating on Neurocrine (NBIX)

Laura Chico

Wedbush

€162.42→€170.32

Buy

26.49%

Upside

Reiterated

08/03/26

Neurocrine price target raised to $194 from $185 at WedbushNeurocrine price target raised to $194 from $185 at Wedbush

Sumant Kulkarni

Canaccord Genuity

€175.59→€184.37

Buy

36.93%

Upside

Reiterated

08/03/26

Neurocrine (NBIX) Receives a Buy from Canaccord Genuity

Danielle Brill

Truist Financial

€187

Buy

38.88%

Upside

Reiterated

08/03/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Bristol-Myers Squibb (NYSE: BMY), Neurocrine (NASDAQ: NBIX) and Genmab (NASDAQ: GMAB)

Ami Fadia

Needham

€175.59→€179.1

Buy

33.01%

Upside

Assigned

07/31/26

Neurocrine Biosciences: Strong Q2 Beat, Upgraded Outlook, and Price Target Raised to $204 Support Buy Rating

Myles Minter

William Blair

―

Buy

―

Reiterated

07/31/26

Neurocrine Biosciences: Strong Q2 Execution, Expanded Pipeline, and Multi-Billion-Dollar Peak Sales Potential Support Buy Rating

Andrew Fein

H.C. Wainwright

€188.76

Buy

40.19%

Upside

Reiterated

07/31/26

Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX), Omnicell (NASDAQ: OMCL) and Guardant Health (NASDAQ: GH)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Jeffrey Walch

Bernstein

€191.39

Buy

42.14%

Upside

Reiterated

09/25/26

Bernstein Remains a Buy on Neurocrine (NBIX)

Brian Abrahams

RBC Capital

€173.83→€164.18

Buy

21.93%

Upside

Reiterated

09/21/26

Neurocrine (NBIX) Gets a Buy from RBC Capital

Unknown Analyst

CCB Intl.

Not Ranked

CCB Intl.

€165.06

Buy

22.58%

Upside

Initiated

09/18/26

Neurocrine (NBIX) Receives a Buy from CCB Intl.

Sean Laaman

Morgan Stanley

€159.79→€160.67

Hold

19.32%

Upside

Assigned

09/11/26

Neurocrine price target raised to $183 from $182 at Morgan StanleyNeurocrine price target raised to $183 from $182 at Morgan Stanley

Yigal Nochomovitz

Citi

€218.61→€222.12

Buy

64.96%

Upside

Reiterated

09/04/26

Neurocrine price target raised to $253 from $249 at CitiNeurocrine price target raised to $253 from $249 at Citi

Cory Kasimov

Evercore ISI

€184.37→€188.76

Buy

40.19%

Upside

Reiterated

08/17/26

Analysts Offer Insights on Healthcare Companies: OmniAb (NASDAQ: OABI), Neurocrine (NASDAQ: NBIX) and Evaxion Biotech (NASDAQ: EVAX)

Evan Seigerman

BMO Capital

€166.81

Hold

23.88%

Upside

Reiterated

08/17/26

Neurocrine (NBIX) Gets a Hold from BMO Capital

David Hoang

Deutsche Bank

€166.81→€144.86

Hold

7.58%

Upside

Assigned

08/13/26

Deutsche Bank Sticks to Its Hold Rating for Neurocrine (NBIX)

Anupam Rama

J.P. Morgan

€162.42→€190.52

Buy

41.49%

Upside

Reiterated

08/06/26

J.P. Morgan Reaffirms Their Buy Rating on Neurocrine (NBIX)

Laura Chico

Wedbush

€162.42→€170.32

Buy

26.49%

Upside

Reiterated

08/03/26

Neurocrine price target raised to $194 from $185 at WedbushNeurocrine price target raised to $194 from $185 at Wedbush

Sumant Kulkarni

Canaccord Genuity

€175.59→€184.37

Buy

36.93%

Upside

Reiterated

08/03/26

Neurocrine (NBIX) Receives a Buy from Canaccord Genuity

Danielle Brill

Truist Financial

€187

Buy

38.88%

Upside

Reiterated

08/03/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Bristol-Myers Squibb (NYSE: BMY), Neurocrine (NASDAQ: NBIX) and Genmab (NASDAQ: GMAB)

Ami Fadia

Needham

€175.59→€179.1

Buy

33.01%

Upside

Assigned

07/31/26

Neurocrine Biosciences: Strong Q2 Beat, Upgraded Outlook, and Price Target Raised to $204 Support Buy Rating

Myles Minter

William Blair

―

Buy

―

Reiterated

07/31/26

Neurocrine Biosciences: Strong Q2 Execution, Expanded Pipeline, and Multi-Billion-Dollar Peak Sales Potential Support Buy Rating

Andrew Fein

H.C. Wainwright

€188.76

Buy

40.19%

Upside

Reiterated

07/31/26

Analysts Offer Insights on Healthcare Companies: Neurocrine (NASDAQ: NBIX), Omnicell (NASDAQ: OMCL) and Guardant Health (NASDAQ: GH)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

OVIDOvid Therapeutics

ESTAEstablishment Labs Holdings

LGNDLigand Pharma

KURAKura Oncology

ZYMEZymeworks

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Neurocrine

3 Months

Jay OlsonOppenheimer

Success Rate

17/26 ratings generated profit

Average Return

+3.18%

Copying Jay Olson's trades and holding each position for 3 Months would result in 65.38% of your transactions generating a profit, with an average return of +3.18% per trade.

1 Year

Laura ChicoWedbush

Success Rate

16/24 ratings generated profit

Average Return

+4.02%

Copying Laura Chico's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +4.02% per trade.

2 Years

Brian SkorneyRobert W. Baird

Success Rate

21/28 ratings generated profit

Average Return

+16.99%

Copying Brian Skorney's trades and holding each position for 2 Years would result in 75.00% of your transactions generating a profit, with an average return of +16.99% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NB3 Analyst Recommendation Trends

Rating

May 26

Jun 26

Jul 26

Aug 26

Sep 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NB3 has received 37 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. NB3 average Analyst price target in the past 3 months is 183.81.

Each month's total comprises the sum of three months' worth of ratings.

NB3 Financial Forecast

NB3 Earnings Forecast

Next quarter’s earnings estimate for NB3 is €1.68 with a range of €1.17 to €2.09. The previous quarter’s EPS was €1.22. NB3 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year NB3 has Performed in-line its overall industry.

NB3 Sales Forecast

Next quarter’s sales forecast for NB3 is €917.72M with a range of €895.51M to €964.87M. The previous quarter’s sales results were €841.96M. NB3 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year NB3 has Performed in-line its overall industry.

NB3 Stock Forecast FAQ

What is DE:NB3’s average 12-month price target, according to analysts?

Based on analyst ratings, Neurocrine’s 12-month average price target is 183.81.

What is DE:NB3’s upside potential, based on the analysts’ average price target?

Neurocrine has 36.51% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Neurocrine a Buy, Sell or Hold?

Neurocrine has a consensus rating of Strong Buy, which is based on 23 buy ratings, 3 hold ratings and 0 sell ratings.

What is Neurocrine’s share price target?

The average share price target for Neurocrine is 183.81. This is based on 26 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €222.12 ,and the lowest forecast is €144.86. The average share price target represents 36.51% Increase from the current price of €134.65.

What do analysts say about Neurocrine?

Neurocrine’s analyst rating consensus is a Strong Buy. This is based on the ratings of 26 Wall Streets Analysts.

How can I buy shares of Neurocrine?

To buy shares of DE:NB3, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Neurocrine (NB3) Stock Forecast & Price Target

NB3 Analyst Ratings

NB3 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Neurocrine

NB3 Analyst Recommendation Trends

NB3 Financial Forecast

NB3 Earnings Forecast

NB3 Sales Forecast

NB3 Stock Forecast FAQ

Detailed List of Analyst Forecasts